3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
355
Leukemia, Myeloid, Acute
297
Myeloproliferative Disorders
155
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
139
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Primary Myelofibrosis
101
Leukemia, Myelomonocytic, Chronic
88
Lymphoma, Non-Hodgkin
76
Leukemia
69
Polycythemia Vera
61
Multiple Myeloma
55
Hodgkin Disease
50
Hematologic Neoplasms
48
Leukemia, Lymphocytic, Chronic, B-Cell
43
Lymphoma
40
Leukemia, Biphenotypic, Acute
40
Thrombocythemia, Essential
39
Myelodysplastic-Myeloproliferative Diseases
31
Neoplasms
29
Leukemia, Myeloid, Chronic-Phase
28
Anemia, Refractory, with Excess of Blasts
24
Recurrence
22
Anemia, Aplastic
21
Lymphoma, Mantle-Cell
20
Lymphoma, Follicular
20
Hematologic Diseases
20
Burkitt Lymphoma
20
Blastic Plasmacytoid Dendritic Cell Neoplasm
20
Blast Crisis
20
Histiocytosis, Langerhans-Cell
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Connective Tissue
×
Myeloid
×
1 year
×
Clear all
NCT04996875
2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2
Recruiting
140 enrolled